2+ is the primary trigger of contraction of gastrointestinal (GI) smooth muscles. However, increasing the Ca 2+ sensitivity of the myofilaments by elevating myosin light chain phosphorylation also plays an essential role. Inhibiting myosin light chain phosphatase activity with protein kinase C-potentiated phosphatase inhibitor protein-17 kDa (CPI-17) and myosin phosphatase targeting subunit 1 (MYPT1) phosphorylation is considered to be the primary mechanism underlying myofilament Ca 2+ sensitization. The relative importance of Ca 2+ sensitization mechanisms to the diverse patterns of GI motility is likely related to the varied functional roles of GI smooth muscles. Increases in CPI-17 and MYPT1 phosphorylation in response to agonist stimulation regulate myosin light chain phosphatase activity in phasic, tonic, and sphincteric GI smooth muscles. Recent evidence suggests that MYPT1 phosphorylation may also contribute to force generation by reorganization of the actin cytoskeleton. The mechanisms responsible for maintaining constitutive CPI-17 and MYPT1 phosphorylation in GI smooth muscles are still largely unknown. The characteristics of the cell-types comprising the neuroeffector junction lead to fundamental differences between the effects of exogenous agonists and endogenous neurotransmitters on Ca 2+ sensitization mechanisms. The contribution of various cell-types within the tunica muscularis to the motor responses of GI organs to neurotransmission must be considered when determining the mechanisms by which Ca 2+ sensitization pathways are activated. The signaling pathways regulating Ca 2+ sensitization may provide novel therapeutic strategies for controlling GI motility. This article will provide an overview of the current understanding of the biochemical basis for the regulation of Ca 
Introduction
Contraction of gastrointestinal (GI) smooth muscles is primarily regulated by the intracellular Ca 2+ signal. Excitatory contractile agonists elevate the cytosolic Ca 2+ concentration ([Ca 2+ ] i ) by triggering Ca 2+ influx from the extracellular space, by activating Ltype Ca 2+ channels and non-selective cation currents, along with Ca 2+ release from intracellular stores. 1 The elevation of [Ca 2+ ] i increases Ca 2+ -bound calmodulin, activating myosin light chain kinase (MLCK), which then phosphorylates the 20-kDa regulatory myosin light chain (MLC) at S19, stimulating myosin ATPase activity, and thereby activating cross-bridge cycling and contraction. [2] [3] [4] [5] Termination of the contractile stimulus leads to a decrease in [Ca 2+ ] i , thereby decreasing MLCK activity. Consequently, MLC is dephosphorylated by the action of myosin light chain phosphatase (MLCP). 6, 7 The reversible phosphorylation of MLC thus plays a central role in the regulation of the contractile responses of GI smooth muscles. However, it is also well known that the relationship between the extent of the [Ca 2+ ] i elevation and the strength of the developed tension varies depending on the stimulus. 5, 8, 9 In general, receptor-mediated contractile stimuli produce more tension for a given elevation of [Ca 2+ ] i than membrane depolarization alone. [10] [11] [12] [13] The Ca
2+
-tension relationship also changes during the time course of the contraction, with the sustained phase of the contraction maintained by a relatively lower level of [Ca 2+ ] i .
14 Phasic, tonic, and sphincter GI smooth muscles thus also exhibit different Ca 2+ -tension relationships that reflect their different functional contractile behaviors. [15] [16] [17] Biochemically, the Ca 2+ -tension relationship is altered by adjusting the balance between MLCK and MLCP activities to increase or decrease MLC phosphorylation. 5, 18, 19 Inhibiting MLCP while activating MLCK further tilts the balance toward MLCK, generating "extra" force by further increasing MLC phosphorylation. Since more force is generated at a given Ca 2+ concentration, this phenomenon was termed "Ca 2+ sensitization of the contractile apparatus," to refer to the apparent increase in Ca 2+ sensitivity of the contractile response. 18 The activity of MLCP is the key determinant of myofilament Ca 2+ sensitization and is regulated by upstream signaling pathways. 20, 21 Once thought to only constitutively reverse MLC S19 phosphorylation by MLCK, MLCP is now known to function as a signal processor under complex regulatory control. 20, 22 Inhibition of MLCP activity and generation of Ca 2+ sensitization can be mediated directly by phosphorylation of the myosin phosphatase targeting subunit 1 of MLCP (MYPT1) and/or indirectly by phosphorylation of a protein kinase C (PKC)-potentiated phosphatase inhibitor protein-17 kDa (CPI-17). 23, 24 Although several possible phosphorylation sites on MYPT1 have been reported, the T696 and T853 sites (numbering of the human isoform) are the most extensively studied and have been confirmed to be important for the inhibition of MLCP activity. 5, 25, 26 Likewise, phosphorylation of CPI-17 at T38 is the most extensively studied and can potentiate its inhibition of MLCP. 27 As a result, similar to other smooth muscles, the contraction of GI smooth muscles is subject to dual regulation by the Ca 2+ signal and alteration of the Ca 2+ sensitivity of the contractile apparatus ( Figure) . Investigations during the last several years have revealed the details of the biochemical basis for the regulation and functional roles of Ca 2+ sensitization mechanisms in GI smooth muscles. However, due to the variety of different approaches, smooth muscle types, and animal models utilized in such studies, there is still an incomplete understanding 
Myosin Light Chain Phosphatase Structure and Regulation
MLCP is a heterotrimeric holoenzyme composed of the 38 kDa catalytic subunit of type 1 protein phosphatase (PPP1C, δ isoform), and the 110 kDa and 20 kDa non-catalytic subunits. 21, 28, 29 The free catalytic subunit of PPP1C displays broad substrate specificity in vitro. 30 Thus PPP1C in vivo is typically found in a complex with different proteins (termed PPP1C-binding proteins, PBPs) which confer different substrate specificities to PPP1C. 30 PBPs allosterically alter the substrate specificity of PPP1C through proteinprotein interactions and by localizing PPP1C in close proximity to the desired substrate. 31, 32 Both mechanisms, which are not mutually exclusive, can increase the rate of substrate dephosphorylation by up to several orders of magnitude. 33 The 110 kDa PBP subunit binds to myosin, targeting PPP1C to myosin filaments, and is referred to as the myosin phosphatase targeting subunit (MYPT). 34, 35 There are several isoforms of MYPT, but MYPT1 (PPP1R12A) is the major isoform expressed in GI smooth muscle. 25 In addition to targeting PPP1Cδ to myosin filaments, MYPT1 increases the substrate specificity of PPP1Cδ toward myosin, and, through its phosphorylation status, regulates the enzymatic activity of PPP1Cδ. 21, 25 There are also splice variants of MYPT1, in which the leucine zipper (LZ) motifs are either present (LZ+) or absent (LZ-). 36 The relative expression levels of LZ+ and LZ-MYPT1
isoforms are an important determinant of the sensitivity of smooth muscles to nitric oxide. 37, 38 The LZ domain has been demonstrated to be required for cGMP-dependent protein kinase to phosphorylate MYPT1 at S668 and increase MLCP activity. [39] [40] [41] thus plays a critical role in the regulation of MLCP activity and smooth muscle excitability. The 20 kDa subunit, referred to as sm-M20 (PPP1R12B), binds to the C-terminal region of MYPT1. The sequence of M20 resembles the C-terminal region of MYPT1 and contains 3 leucine zippers. 42 A smaller splice variant of M20 lacks the leucine zippers. 35 Although the functional role of M20 is still not clear, the heart-specific small subunit of MLCP (HS-M21) was shown to increase the Ca 2+ sensitivity of contraction of permeabilized renal arterial smooth muscle and cardiomyocytes, and increase the Ca 2+ sensitivity of cardiac muscle contraction. 43, 44 Relative Importance of MYPT1 and CPI-17 to the Regulation of Myosin Light Chain Phosphorylation by Ca
2+ Sensitization Mechanisms
Changes in MLC phosphorylation are due to net changes in the activities of MLCK and MLCP relative to each other. Thus, the expression levels of MYPT1 and CPI-17 relative to MLCK and MLC are a factor in evaluating their relative importance to the regulation of MLCP activity within a particular smooth muscle tissue. The expression level of MYPT1 can be used as an indicator of the expression level of MLCP, since MYPT1 and PPP1Cδ are present at a 1:1 ratio in the MLCP holoenzyme. 7 The expression levels of both CPI-17 and MYPT1 in GI smooth muscles differ in different regions of the gut that have been examined. Although both MYPT1 and CPI-17 are ubiquitously expressed in GI smooth muscles, the CPI-17 expression level appears to correlate with the extent of PKC-mediated Ca 2+ sensitization of force. 20, 45 An extreme example is the gizzard and aorta from American farm chickens, which lack CPI-17. 46 In these tissues, agonist stimulations induce only a slight increase in the Ca 2+ sensitivity. 46 We found different levels of MYPT1 and CPI-17 in gastric fundus, gastric antrum, and proximal colon of mouse. 47 The gastric fundus has highest levels of Rho-associated, coiled-coil containing protein kinase 2 (ROCK2), MYPT1, and CPI-17 relative to MLCK and MLC. The proximal colon has high levels of MLC, MLCK, CPI-17, and MYPT1, but a low level of ROCK2. The antrum has the lowest levels of CPI-17 and MYPT1, and ROCK2, but high levels of MLC and MLCK. The functional roles of RhoA/ROCK have been examined in smooth muscles from rat internal anal sphincter (IAS), rectum, and the anococcygeus. 48 These studies showed the highest levels of RhoA, GTP-RhoA, ROCK2, MLC, phosphorylated MYPT1 T696, and phosphorylated MLC in the tonic smooth muscles of the IAS compared to the mostly phasic rectum and phasic anococcygeus smooth muscles. CPI-17, phosphorylated CPI-17 T38, and phosphorylated MYPT1 T853 levels were not determined. Overall, these findings from different functional regions of the gut suggest that tonic GI smooth muscles may rely more on Ca 2+ sensitization mechanisms for tone and contractions than phasic smooth muscles, which may rely more on MLCK activity.
Inhibition of Myosin Light Chain Phosphatase Activity by CPI-17 Phosphorylation
CPI-17 (17 kDa PKC-potentiated inhibitory protein of type 1 protein phosphatase, PPP1R14A) is the endogenous heat stable, smooth muscle-specific, inhibitory protein of MLCP. 49, 50 When CPI-17 is phosphorylated at T38, it binds to and inhibits MLCP ( Figure) . 49, 50 Three CPI-17 homologs are found in the human genome, and each one can potently inhibit MLCP activity. 49 ,51,52 CPI-17 can be phosphorylated by multiple kinases. In smooth muscle, CPI-17 phosphorylation occurs in response to agonist stimulation through activation of PKC, ROCK, or integrin-linked kinase (ILK). 24, 53 ,54 PKC appears to be the major kinase that phosphorylates CPI-17 in GI smooth muscles. While PKCα and PKCδ are the primary kinases for CPI-17 phosphorylation in response to agonist stimulation, CPI-17 can also bind to the regulatory domain of PKC isoforms, including α, and the "non-traditional" PKCs ε, λ, ζ, and μ. 55 Zipper-interacting kinase (ZIPK) and p21-activated kinase can also directly phosphorylate isolated CPI-17 at T38. 56, 57 Phosphorylated CPI-17 selectively inhibits MLCP with an IC 50 value of approximately 1 nM, due to the association of the PPP1Cδ catalytic subunit with MYPT1. 58, 59 Computer modeling predicts direct binding between MYPT1 and phospho-CPI-17, suggesting that MYPT1 may dock CPI-17 to the MLCP holoenzyme, accounting for the specific inhibition of MLCP by CPI-17. 60 Furthermore, when bound to MYPT1, the PPP1Cd catalytic subunit of MLCP is unable to hydrolyze phospho-Thr38 of CPI-17, so phospho-CPI-17 is able to bind at the active site of PPP1Cδ and suppress its activity.
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Inhibition of Myosin Light Chain Phosphatase Activity by MYPT1 Phosphorylation
It is well established that MLCP activity is regulated by Ser/ Thr phosphorylation of MYPT1. Although several MYPT1 phosphorylation sites have been identified, 2 Thr residues (ie, T694 and T852; T697 and T855; T696 and T853, mouse, rat, and human isoform numbering, respectively) are the most important for eliciting Ca 2+ sensitization. 25 Several protein kinases, including ROCK, ZIPK, ILK, myotonic dystrophy kinase, Raf-1 and p21-activated protein kinases are known to phosphorylate the T696 residue. 21, 26 ROCK appears to be the major kinase phosphorylating MYPT1 at T853 in comparison to the other MYPT1 kinases. 23, 24, 61 There are 2 isoforms of ROCK, ROCK1 and 2, which have similar tissue distributions and share 65% sequence homology at the amino acid level. 62, 63 In addition to regulating MLC phosphorylation via MYPT1 phosphorylation and inhibition of MLCP activity, both ROCK isoforms are important regulators of cell growth, migration, and morphology via control of actin cytoskeletal assembly. 63 Despite their sequence similarity and overlapping substrate specificities, gene-silencing and selective knock-out models indicate distinct roles for each isoform. 63 Although both ROCK1 and ROCK2 can phosphorylate MYPT1 at T853, only ROCK2 can directly bind to MYPT1, resulting in a greater degree of T853 phosphorylation. 64 In addition, in vascular smooth muscles, the myosin phosphataserho interacting protein (MP-RIP, also M-RIP, p116 RIP ) co-localizes GTP-RhoA with ROCK2 bound to MYPT1 to selectively stimulate ROCK2 phosphorylation of MYPT1 T853. 64, 65 We found that M-RIP is expressed in murine gastric antrum, gastric fundus, and proximal colon smooth muscles, suggesting that a similar mechanism is present in GI smooth muscle tissues. 47 ROCK shows a 3-fold preference for T853 rather than T696, while the ZIPK shows a 6.7-fold preference for T696 over T853. 66 Both of these inhibitory phosphorylation sites are immediately preceded by Ser residues that match the cyclic AMP-and cGMP-dependent protein kinase consensus phosphorylation motif. 67 Phosphorylation of S695 interferes with subsequent inhibitory phosphorylation of T696 by ROCK, causing a decrease in MLCP inhibition, and potentially, an increase in MLC dephosphorylation. 67 Whether S852 phosphorylation has a similar effect on T853 phosphorylation by ROCK has not yet been investigated. 67 Other signaling pathways that impact the activities of these kinases thus have the potential to indirectly affect MLCP activity also. Much effort has been directed toward the determining the functional consequences and the physiological importance of MYPT1 phosphorylation at these two inhibitory threonine residues. 21 Currently, phosphorylation of T696 is thought to directly inhibit MLCP activity towards MLC, via pseudosubstrate inhibition, whereas T853 phosphorylation is believed to cause dissociation of MLCP from myosin and/or inhibit MLCP activity directly. 68 The latter hypothesis is supported by the recent study using a genetic approach to knock-in nonphosphorylatable Ala for T852 or T694. 69 The MYPT1 T694A mutation was found to significantly inhibit sustained force as well as MLC phosphorylation, while the T852A mutation had no significant effect on maximal force development and little effect on force maintenance in neonatal bladder smooth muscle. These findings indicate that phosphorylated T694, but not T852, inhibits MLCP activity. However, ROCK inhibitors still inhibited force development and force maintenance in bladder smooth muscles with the T852A mutation to similar extents as wild-type muscles, without affecting MLC phosphorylation. 69 Why did the T852 mutation have no significant effect on maximal force development and little effect on force maintenance in bladder smooth muscle, and yet ROCK inhibitors were still able to inhibit contractile responses? Much of the evidence supporting a role of MYPT1 T852 phosphorylation in contributing to enhanced MLC phosphorylation in intact tissues has been obtained using pharmacological inhibitors of ROCK. Although we observed a decrease in constitutive MLC S19 phosphorylation in mouse gastric fundus smooth muscles with the ROCK inhibitor Y-26732, both MYPT1 T852 and T694 phosphorylation were reduced by Y-26732. 47 ROCK inhibition also reduced the carbachol (CCh)-evoked increase in MLC S19 phosphorylation, but also inhibited the increase in MYPT1 T852 and T694 phosphorylation. 70 Furthermore, as noted earlier, both ROCK isoforms phosphorylate other proteins that can potentially affect smooth muscle contraction.
In rat aorta and mesenteric arteries, ROCK appears to be involved in agonist activation of Ca 2+ entry distinct from voltage or store operated channels. 71 Treatment of rat resistance arteries with a ROCK inhibitor inhibited F-actin polymerization and contraction. 72 ROCK can also affect actin dynamics through the phosphorylation of LIM-kinase, which phosphorylates and inactivates cofilin's ability to sever F-actin. [73] [74] [75] The resulting increase in actin polymerization is associated with enhanced force development by linking the actomyosin motor complex to the extracellular matrix through membrane adhesions. 76 The ROCK inhibitors Y-27632 and H-1152 have also been shown to decrease the contractions of mouse colon smooth muscles evoked by nerve stimulation, CCh and substance P partly by inhibition of non-selective cation conductances. 77 Finally, the commonly used ROCK inhibitors Y-26732, HA-1152, and fasudil, are nonselective with respect to ROCK1 and ROCK2. 63 Thus, the use of pharmacological ROCK inhibitors will affect the activities of both ROCK1 and ROCK2, and not only inhibit MYPT1 T852 phosphorylation, but also affect multiple proteins involved in smooth muscle contraction. It has been reported that the ROCK inhibitor Y-27632 inhibits gastric motility in vivo in rats. 81 In gastric fundus smooth muscles, ROCK inhibitors, but not PKC inhibitors, suppress the contractile responses to CCh, KCl, and cholinergic neurotransmission evoked by electrical field stimulation, and also relaxed fundus smooth muscles pre-contracted by CCh or KCl. 82, 83 In isolated, permeabilized cells from guinea pig gastric fundus, PKC inhibitors did not inhibit CCh-induced cell shortening, although another study showed that PKC inhibitors do inhibit CCh-induced cell shortening. 84, 85 Similarly, ROCK inhibitors, but not PKC inhibitors, inhibited GTPand CCh-induced Ca 2+ sensitization in proximal colon longitudinal smooth muscles. 86 In longitudinal smooth muscles from the distal colon, both ROCK and PKC inhibitors inhibited GTP-and CChinduced Ca 2+ sensitization. 86 However, in circular smooth muscles from the distal colon, PKC inhibitors but not ROCK inhibitors inhibited CCh-induced Ca 2+ sensitization. 86 In rectal smooth muscles from the rat, ROCK inhibition significantly decreased spontaneous contractions and ROCK activity, but to lesser extents than in IAS smooth muscles. 48 In mouse anococcygeus smooth muscle, Ca 2+ sensitization induced by phenylephrine, norepinephrine, and CCh was markedly antagonized by ROCK inhibitors, and the contractile responses to KCl-induced depolarization or excitatory electrical field stimulation were also highly sensitive to ROCK inhibitors. 87, 88 The phosphorylation of MYPT1, CPI-17, and MLC in various GI smooth muscles in response to contractile agonists has been investigated by a number of laboratories. These studies show that, in general, exogenously added contractile agonists elicit variable increases in MLC S19, CPI-17 T38, and MYPT1 T694 and T852 phosphorylation depending on the agonist used and the smooth muscle employed. In murine gastric fundus smooth muscles we found that CCh increases ROCK-dependent MYPT1 T852, but not T694, phosphorylation, and PKC-dependent CPI-17 T38 phosphorylation. 70 Atropine-sensitive cholinergic neurotransmission evoked by electrical field stimulation only increased CPI-17 T38 phosphorylation. 70 MLC S19 phosphorylation was only modestly increased by CCh stimulation. 70 In murine gastric antrum smooth muscles we found that CCh or high extracellular K + increased the phosphorylation of CPI-17 T38 and MYPT1 T852, and modestly increased MYPT1 T694 phosphorylation. 89 In gastric antrum smooth muscles from diabetic ob/ob mice, we found similar levels of CPI-17 expression and T38 phosphorylation in response to CCh or high K + . 89 However, ROCK2 expression and MYPT1 T852 phosphorylation were transiently decreased. 89 MLC S19 basal phosphorylation levels, and the increase in S19 phosphorylation by CCh or high K + were also lower in ob/ob gastric antrum smooth muscles. 89 In longitudinal smooth muscles from the rat ileum, CCh increases ROCK-dependent MYPT1 T853, but not T697, phosphorylation, and PKC-dependent CPI-17 T38 phosphorylation. 90, 91 PKC inhibition inhibited T38 phosphorylation, while ROCK inhibitors inhibited both T855 and T38 phosphorylation. [90] [91] [92] CPI-17 expression and phosphorylation, and MLC phosphoryl-ation are decreased in animal models of colitis, and in human patients with ulcerative colitis. 93, 94 ROCK and MYPT1 phosphorylation contribute substantially to the constitutive tonic contracted state of the IAS. 95 ROCK inhibition decreases the basal tone, and reduces the phosphorylation levels of MYPT1 T697, CPI-17 T38, and MLC S19 in rat IAS smooth muscles. 48, 95 With human IAS smooth muscles, it has been reported that PKC inhibitors significantly decrease T38 phosphorylation, with modest effects on IAS smooth muscle tone, while ROCK inhibition produces significantly greater relaxation of IAS smooth muscle cells than PKC inhibition. 95, 96 However, it has also been reported that the PKC activator PDBu relaxes opossum IAS. 97 A variety of non-cholinergic agonists have been reported to increase CPI-17 and MYPT1 phosphorylation and activate myofilament Ca 2+ sensitization. In cultured cells isolated from rabbit distal stomach smooth muscles, motilin increased the phosphorylation of CPI-17 by PKC and MYPT1 by ROCK, leading to inhibition of MLCP and sustained MLC phosphorylation and contraction. 98 In contrast, lysophosphatidic acid increased CPI-17 phosphorylation by PKC, but although ROCK was activated, MYPT1 phosphorylation at T696 was masked by MYPT1 phosphorylation at S695. 99 The PAR2 activating peptide SLIGRL (PAR2-AP) increased MYPT1 phosphorylation but not CPI-17 phosphorylation in cultured cells isolated from rabbit distal stomach smooth muscles. 99 Androgens have recently been shown to potentiate ileal and colonic smooth muscle contractions by a non-genomic mechanism involving stimulation of polyamine synthesis which induces calcium sensitization of contractile machinery by ROCK and PKC activation along with increased CPI-17 phosphorylation. 100 Angiotensin IIinduced contractions of rat LES and IAS smooth muscle cells are inhibited by Clostridium botulinum C3 exozyme, HA-1077, and Y-27632, suggesting a role for ROCK. 101 It has been reported that thromboxane A2 and prostaglandin F2α, the end products of the renin-angiotensin system and arachidonic acid pathways, increase IAS tone via activation of RhoA/ROCK and increased MYPT1 T696 and MLC S19 phosphorylation.
Activation of Ca 2+ Sensitization Mechanisms in Gastrointestinal Smooth Muscles
101-103
Other This study showed that PKC, ERK1/2, and p38MAPK pathways facilitate the microcystin-induced contraction at low Ca 2+ concentrations by contributing to the inhibition of MLCP activity through phosphorylation of MYPT1 or CPI-17. Previous reports suggested several candidates for MLC di-phosphorylation by Ca 2+ -independent MLCKs including ROCK, PKC, MAPK-activated protein kinase-2 (MAPKAPK2), MAPK-activated protein kinase1b (RSK-2), ILK, and ZIPK. 53, [106] [107] [108] [109] [110] [111] Among these kinases, only ROCK and ILK have been shown to induce MLC phosphorylation and contraction of ileum smooth muscles. 53, 106 Taken together, ILK has emerged as the likely candidate to fill the role of Ca 2+ -independent MLCK for the di-phosphorylation of MLC in GI smooth muscle. 112 In addition, it was recently reported that ERK and p38MAPK contribute to Ca 2+ sensitization of ileal longitudinal smooth muscle contraction and regulate MLCP activity independently of MYPT1
and CPI-17 phosphorylation. 113 ERK or p38MAPK inhibitors inhibited CCh-induced contractile force and decreased MLCP activity, as measured by phosphatase activity in lysates. However, MYPT1 T697 and T855, and CPI-17 T38 phosphorylation were not affected by MEK or p38MAPK inhibition. Thus, ERK and p38MAPK may contribute to CCh-induced sustained contraction in an MLC phosphorylation dependent manner, and inhibit MLCP activity by a novel mechanism.
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CPI-17 and MYPT1 Are Constitutively Phosphorylated in Gastrointestinal Smooth Muscles
Some of the evidence for the constitutive phosphorylation of CPI-17 and MYPT1 in GI smooth muscles comes from studies investigating the effects of PKC and ROCK inhibitors on spontaneous tone. In the LES, ROCK inhibitors have been shown to produce full relaxation of the basal tone in human and various animal species, while PKC inhibitors have only limited effects on LES basal tone. 17, 80 These studies suggest that a mechanism of Ca 2+ sensitization mediated by the RhoA/ROCK pathway plays an important role in the basal tone in the LES, although MYPT1 and CPI-17 phosphorylation in the LES has not been measured. Interestingly, the proton pump inhibitor pantoprazole inhibited MYPT1 T853 phosphorylation evoked by CCh in gastric and LES tissue, suggesting that it may also be a ROCK inhibitor, although it had no effect on constitutive MYPT1 or CPI-17 phosphorylation. 114 It has been reported that PDBu-evoked contraction of cells isolated from human IAS smooth muscles are reduced by a ROCK inhibitor, but not by a PKC inhibitor, although PKC was activated, although another study reported that PDBu relaxes opossum IAS smooth muscles and cells isolated from opossum IAS smooth muscles. 97, 115 Several of the studies previously mentioned examining CPI-17 and MYPT1 phosphorylation in response to contractile agonists show variable, but significant levels of constitutive CPI-17 and MYPT1 phosphorylation in the un-stimulated control tissues. In GI smooth muscles that have been examined, constitutive CPI-17 phosphorylation is low, while MYPT1 phosphorylation at T694 and T852 is quite significant. 47, 70, 89, 98, 105, [116] [117] [118] [119] Typically, PKC inhibitors decrease the constitutive phosphorylation of CPI-17 at T38, and ROCK inhibitors decrease the constitutive phosphorylation of MYPT1 at T853. 22, 120 However, the sensitivity of constitutive CPI-17 T38
and MYPT1 T696 phosphorylation to PKC and ROCK inhibitors varies among different GI smooth muscles. ROCK inhibitors have no effect on basal T38 phosphorylation in the gastric fundus, antrum, and proximal colon, but partially decrease basal T38 phosphorylation in the ileum, IAS, and rectum. 47, 48 Basal T696 phosphorylation is partially decreased by nifedipine, PKC inhibitors, or ROCK inhibitors in IAS, ileum, or gastric fundus, while in rectum, only ROCK inhibitors partially decrease basal T696 basal phosphorylation. 47, 48 In gastric antrum and proximal colon, PKC or ROCK inhibitors have no effect on basal T696 phosphorylation. 47 These findings suggest that tissue specific mechanisms likely regulate T696 phosphorylation in GI smooth muscles, with ROCK and PKC involved in maintaining pT696 in gastric fundus, ileum, rectum, and IAS smooth muscles, but not in antrum and proximal colon smooth muscles. Additional kinases can phosphorylate T696 in vivo, including MYPT1 kinase, integrin-linked kinase, myotonic dystrophy protein kinase, p21-activated protein kinase, and Raf-1. 57, [121] [122] [123] [124] [125] Which kinases maintain constitutive MYPT1 T696 phosphorylation in the gastric antrum and proximal colon smooth muscles have not been identified. The study of embryonic bladder smooth muscle by Chen et al. showed that the constitutive MYPT1 T694 phosphorylation was not further increased by phosphatase inhibition. 69 In addition, the MYPT1 T694A mutation resulted in significantly decreased force generation and reduced MLC20 phosphorylation. 69 These findings indicate that MYPT1 T694 may be 100% phosphorylated, and is responsible for suppressing MLCP activity under resting conditions. 69 Interestingly, these findings may explain why MYPT1 T694 phosphorylation is sometimes not further increased by contractile agonists. 70 Finally, basal CPI-17 and MYPT1 phosphorylation has typically been measured in GI smooth muscles in which motor nerve activity is blocked with tetrodotoxin. However, ongoing kinase activity must be present to maintain this basal CPI-17 and MYPT1 phosphorylation. What are the mechanisms underlying the constitutive kinase activities that sustain CPI-17 and MYPT1 phosphorylation in the absence of motor neuron stimulation? Because of the importance of the basal phosphorylation levels of CPI-17 and MYPT1 for basal tone and in setting the sensitivity of the contractile machinery to neuronal stimulation, unraveling the mechanisms responsible for the basal kinase activities in the absence of neural signals is important for a more complete understanding of GI smooth muscle contraction.
Exogenous vs Endogenous Cholinergic Stimulation
Only a few studies have examined the stimulation of Ca 2+ sensitization in GI smooth muscles by endogenous neurotransmission. Because the constitutive phosphorylation of CPI-17 and MYPT1 is important for maintaining basal tone and in setting the sensitivity of the contractile machinery to contractile stimuli, determining the mechanisms maintaining these basal kinase activities is important for a more complete understanding of GI smooth muscle contraction. Genetic knock-in of non-phosphorylatable MYPT1 T694A and T852A mutants suggest that phosphorylated T694 is responsible for direct MLCP inhibition, while phosphorylated T852 may mediate the effects of ROCK on enhancing force development through dynamic reorganization of the actin cytoskeleton at membrane adhesions connected to the extracellular matrix. Due to the localized nature of neurotransmitter release from motor neuron varicosities, and the contribution of the specialized ICC to neurotransmission in GI smooth muscles, Ca 2+ sensitization mecha- sensitization mechanisms may be altered in pathophysiological conditions affecting GI motility. It will be important to elucidate how the mechanisms and signaling pathways underlying Ca 2+ sensitization are altered during GI dysmotilities. This will help us to not only better understand GI smooth muscle pathophysiology, but also help develop new pharmacological strategies for the treatment of GI motility disorders.
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